A Phase 2 interventional study of Ramucirumab and Icrucumab in Colon Cancer and Rectal Cancer, sponsored by Eli Lilly and Company. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-06.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Colonic Neoplasms by Eli Lilly and Company — none open to participants now, 4 under way, none of them phase 3. Colonic Neoplasms · Eli Lilly and Company.
Among the 11 studies in Colonic Neoplasms by Eli Lilly and Company, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 2, and was the 4th registered.
2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.
Browse Colonic Neoplasms studies →None of the 11 studies in Colonic Neoplasms by Eli Lilly and Company is open now. The open studies under Colonic Neoplasms, anywhere →
Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6
First in 2005; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 75 across 1,710 interventional studies indexed under Colonic Neoplasms.
Median enrollment 71 across the 10 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Colonic Neoplasms by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard chemotherapy plus icrucumab.
The purpose of this study is to evaluate the progression-free survival (PFS) in participants with metastatic colorectal cancer when treated with 1 of 3 modified FOLFOX-6 (folinic acid [FA] + fluorouracil [5-FU] + oxaliplatin [mFOLFOX-6])-based regimens, as second-line therapy.
During 2010, there has been an identified shortage of injectable folinic acid (FA) in the United States. Levo-folinic acid (LFA) will be allowed as a substitute for FA in the mFOLFOX-6 chemotherapy regimen in circumstances in which FA is not available, to facilitate continuity of participant care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
mFOLFOX-6
Drug: mFOLFOX-6
mFOLFOX-6 + Ramucirumab
Biological: Ramucirumab · Drug: mFOLFOX-6
mFOLFOX-6 + Icrucumab
Biological: Icrucumab · Drug: mFOLFOX-6
8 mg/kg IV Q2W
Also known as: IMC-1121B, LY3009806
15 mg/kg IV Q2W
Also known as: IMC-18F1, LY3012212
Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W) FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable). 5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W
Progression-Free Survival (PFS)
PFS is defined as the time from baseline until the date of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever was first. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress, are lost to follow-up, or have missed two or more scheduled tumor assessments will be censored at the day of their last radiographic tumor assessment, if there are no post-baseline tumor measurements for a randomized and treated participant, the participant will be censored at the date of randomization. If death or progressive disease (PD) occurs after 2 or more missing radiographic visits, censoring will occur at the date of the last radiographic visit prior to the last visit.
Time frame: Baseline until Disease Progression or Death from Any Cause (Up to 95 Weeks)
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
The ORR is the percentage of participants with Complete Response (CR, the disappearance of target lesions and any pathological lymph nodes \[target or non-target\] taking as reference the baseline sum of diameters in response to treatment) or Partial Response (PR, at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters in response to treatment) according to RECIST v1.1 from the start of the treatment until disease progression.
Time frame: Baseline until Disease Progression (Up to 95 Weeks)
Overall Survival (OS)
Overall survival is defined as the time from baseline to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive.
Time frame: Baseline Until Death from Any Cause (Up to 163 Weeks)
Duration of Response (DoR)
DoR was measured from the time measurement criteria are first met for Complete Response or Partial Response or until the first date that the criteria for disease progression or death from any cause. whichever is first recorded. As defined according to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, and PR is the short axes of any target lymph nodes reduced to \< 10 mm and at least a 30% decrease in the sum of the diameters of target lesions including the short axes of any target lymph nodes.)
Time frame: Criteria First Met for CR or PR until Disease Progression or Death from Any Cause (Up to 95 Weeks)
Pharmacokinetics (PK): Maximum Concentration (Cmax) at Cycle 5
Maximum concentration (1 hour post end of infusion, Cmax) is the concentration measured in serum.
Time frame: Cycle 5, 1 Hour Post End of Infusion
Pharmacokinetics (PK): Trough Serum Concentrations (Ctrough) at Cycle 5
Trough (prior to infusion, Ctrough) concentrations measured in serum.
Time frame: Cycle 5, Prior to Infusion
Maximum Concentration (Cmax) at Day 8
Maximum concentration (Cmax) is the maximum peak concentration measured in blood plasma after drug infusion.
Time frame: Day 8 (cycles 1 and 5)
Maximum Concentration (Cmax) at Day 15
Cmax is the maximum peak concentration measured in blood plasma after drug infusion.
Time frame: Day 15 (Cycles 1 and 5)
Minimum Concentration (Cmin) at Day 1
Cmin is the minimum peak concentration measured in blood plasma after drug infusion.
Time frame: Day 1 (cycles 1, 5, 9, and 13)
Minimum Concentration (Cmin) at Day 4
Cmin is the minimum peak concentration measured in blood plasma after drug infusion.
Time frame: Day 4 (cycles 1 and 5)
Minimum Concentration (Cmin) at Day 8
Minimum concentration (Cmin) is the minimum peak concentration measured in blood plasma after drug infusion.
Time frame: Day 8 (cycles 1 and 5)
Minimum Concentration (Cmin) at Day 15
Minimum concentration (Cmin) is the minimum peak concentration measured in blood plasma after drug infusion.
Time frame: Day 15 (cycles 1 and 5)
Number of Participants With Serum Ramucirumab Antibody Assessment
A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.
Time frame: 31 Weeks
Serum Anti-Icrucumab Antibody Assessment
A sample will be considered positive for anti-icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-icrucumab antibody level seen in healthy untreated individuals.
Time frame: 31 Weeks
Number of Participants With Adverse Events
A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline up to 165 weeks
| Milestone | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|---|
| Started | 54 | 52 | 52 |
| Received at least one dose of study drug | 49 | 52 | 52 |
| Completed | 46 | 52 | 49 |
| Not completed | 8 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrew consent | 3 | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Met exclusion criteria | 2 | 0 | 0 |
PFS is defined as the time from baseline until the date of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever was first. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress, are lost to follow-up, or have missed two or more scheduled tumor assessments will be censored at the day of their last radiographic tumor assessment, if there are no post-baseline tumor measurements for a randomized and treated participant, the participant will be censored at the date of randomization. If death or progressive disease (PD) occurs after 2 or more missing radiographic visits, censoring will occur at the date of the last radiographic visit prior to the last visit.
| Weeks | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|---|
| Progression-Free Survival (PFS) | 18.4 (15.7 to 24.4) | 21.4 (16.1 to 25.0) | 15.9 (14.1 to 16.4) |
The ORR is the percentage of participants with Complete Response (CR, the disappearance of target lesions and any pathological lymph nodes \[target or non-target\] taking as reference the baseline sum of diameters in response to treatment) or Partial Response (PR, at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters in response to treatment) according to RECIST v1.1 from the start of the treatment until disease progression.
| percentage of participants | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|---|
| Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 14 (5.94 to 27.24) | 3.8 (0.47 to 13.21) | 3.8 (0.47 to 13.21) |
Overall survival is defined as the time from baseline to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive.
| Weeks | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|---|
| Overall Survival (OS) | 53.6 (36.1 to 68.4) | 41.7 (28.4 to 60.3) | 42.0 (32.0 to 50.4) |
DoR was measured from the time measurement criteria are first met for Complete Response or Partial Response or until the first date that the criteria for disease progression or death from any cause. whichever is first recorded. As defined according to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, and PR is the short axes of any target lymph nodes reduced to \< 10 mm and at least a 30% decrease in the sum of the diameters of target lesions including the short axes of any target lymph nodes.)
| Weeks | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|---|
| Duration of Response (DoR) | 35.6 (4.0 to NA) | NA (NA to NA) | NA (8.1 to NA) |
Maximum concentration (1 hour post end of infusion, Cmax) is the concentration measured in serum.
| microgram/milliliter (µg/mL) | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) at Cycle 5 | NA ± NA | 201 ± 88 |
Trough (prior to infusion, Ctrough) concentrations measured in serum.
| µg/mL | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|
| Pharmacokinetics (PK): Trough Serum Concentrations (Ctrough) at Cycle 5 | 53.6 ± 123 | 146 ± 32 |
Maximum concentration (Cmax) is the maximum peak concentration measured in blood plasma after drug infusion.
No measurements were reported for this outcome.
Cmax is the maximum peak concentration measured in blood plasma after drug infusion.
No measurements were reported for this outcome.
Cmin is the minimum peak concentration measured in blood plasma after drug infusion.
No measurements were reported for this outcome.
Cmin is the minimum peak concentration measured in blood plasma after drug infusion.
No measurements were reported for this outcome.
Minimum concentration (Cmin) is the minimum peak concentration measured in blood plasma after drug infusion.
No measurements were reported for this outcome.
Minimum concentration (Cmin) is the minimum peak concentration measured in blood plasma after drug infusion.
No measurements were reported for this outcome.
A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.
| Participants | mFOLFOX-6 + Ramucirumab |
|---|---|
| Number of Participants With Serum Ramucirumab Antibody Assessment | 0 |
A sample will be considered positive for anti-icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-icrucumab antibody level seen in healthy untreated individuals.
No measurements were reported for this outcome.
A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.
| Participants | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|---|
| Any TEAE | 49 | 52 | 52 |
| Any SAE | 11 | 18 | 12 |
| Any Grade ≥3 AE | 30 | 37 | 31 |
| Any AE leading to discontinuation (any drug) | 6 | 18 | 11 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| mFOLFOX-6 | 37/49 (75.5%) | 11/49 (22.4%) | 48/49 (98%) |
| mFOLFOX-6 + Ramucirumab | 41/52 (78.8%) | 18/52 (34.6%) | 52/52 (100%) |
| mFOLFOX-6 + Icrucumab | 40/52 (76.9%) | 12/52 (23.1%) | 52/52 (100%) |
| Event | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/49 | 1/52 | 3/52 |
| VomitingGastrointestinal disorders | 2/49 | 0/52 | 2/52 |
| SepsisInfections and infestations | 2/49 | 0/52 | 1/52 |
| FatigueGeneral disorders | 0/49 | 2/52 | 1/52 |
| Bile duct obstructionHepatobiliary disorders | 0/49 | 2/52 | 0/52 |
| DehydrationMetabolism and nutrition disorders | 0/49 | 0/52 | 2/52 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/49 | 0/52 | 2/52 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/49 | 1/52 | 0/52 |
| CataractEye disorders | 1/49 | 0/52 | 0/52 |
| Abdominal painGastrointestinal disorders | 1/49 | 1/52 | 0/52 |
| Event | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab |
|---|---|---|---|
| FatigueGeneral disorders | 35/49 | 45/52 | 36/52 |
| NauseaGastrointestinal disorders | 30/49 | 24/52 | 36/52 |
| Peripheral sensory neuropathyNervous system disorders | 27/49 | 25/52 | 32/52 |
| DiarrhoeaGastrointestinal disorders | 19/49 | 30/52 | 27/52 |
| Oedema peripheralGeneral disorders | 5/49 | 15/52 | 29/52 |
| VomitingGastrointestinal disorders | 17/49 | 13/52 | 27/52 |
| AnorexiaMetabolism and nutrition disorders | 16/49 | 20/52 | 27/52 |
| Abdominal painGastrointestinal disorders | 13/49 | 16/52 | 24/52 |
| Temperature intoleranceGeneral disorders | 21/49 | 13/52 | 18/52 |
| ConstipationGastrointestinal disorders | 12/49 | 18/52 | 19/52 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab | Total |
|---|---|---|---|---|
| Mean | 60.8 ± 9.23 | 59.9 ± 10.95 | 58.2 ± 10.15 | 59.6 ± 10.14 |
| Sex: Female, Male(Participants) | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab | Total |
|---|---|---|---|---|
| Female | 21 | 21 | 29 | 71 |
| Male | 28 | 31 | 23 | 82 |
| Ethnicity (NIH/OMB)(Participants) | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 49 | 52 | 51 | 152 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | mFOLFOX-6 | mFOLFOX-6 + Ramucirumab | mFOLFOX-6 + Icrucumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 7 | 5 | 7 | 19 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 3 | 1 | 0 | 4 |
| White | 35 | 45 | 45 | 125 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 3 | 0 | 0 | 3 |
The record gives a start of Aug 2010, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2019, 5 years 8 months after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Icrucumab